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Fig．１ １２誘導心電図 Fig．２ 胸部レントゲン写真


















































Fig．６ 本例における CTEPH 発生機序の考察
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SUMMARY
A woman in her ６０s presented with shortness of breath on exertion and was admitted to a
nearby hospital in March２００X. Contrast-enhanced computer tomography scan showed contrast
defect images in the pulmonary artery and lower extremity vein. She was diagnosed with pulmo-
nary embolism and deep venous thrombosis and anticoagulant therapy was started. At the same
time, a blood test revealed an abnormal increased platelet count（７４０，０００/µl）, and she was diagnosed
as myeloproliferative disease（primary myelofibrosis, JAK２mutation +）. We follow up with oral
administration of a steroid because she had a low risk of primary myelofibrosis. However, the
symptom had been lasting, she was admitted into our hospital for examining the origin of symptom
and treatment. Cardiac echocardiography suggested the presence of pulmonary hypertension, and
lung ventilation perfusion scintigraphy showed widespread wedge accumulation defect, depressed
area in bilateral lungs, and ventilator blood flow mismatch. In cardiac catheterization, the mean
pulmonary artery pressure was as high as ３７mmHg. Per the test results, she was diagnosed
chronic thromboembolic pulmonary hypertension（CTEPH）secondary to primary myelofibrosis.
We proposed invasive treatment（pulmonary artery endarterectomy, balloon pulmonary arterio-
plasty）, but she desired just oxygen administration and medication therapy.
It is reported that CTEPH develops in an organized thrombus after acute pulmonary embolism,
but the mechanism of that development has not been revealed. In this case with primary
myelofibrosis, we consider that the decrease of pulmonary vascular bed is due to a blood cell
disorder and vascular remodeling is due to an increase of vascular endothelial growth factor and
platelet derived growth factor secreted by abnormal increased platelet contributed to elevation of
pulmonary artery pressure.
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